All updates
All updates
today 28文献与产业新闻评分3232 文献与产业新闻评分3535 STAT+: Pharmalittle: We’re reading about a lawsuit over lab tests for meds, a Bristol myeloma drug, and more
文献与产业新闻精选评分7676 Vimseltinib (romvimza) approved for use in adults to treat tenosynovial giant cell tumours
文献与产业新闻精选评分8181 STAT+: FDA approves Bristol multiple myeloma treatment, marking debut of novel drug class
文献与产业新闻评分4949 After 2 undisclosed gene therapy deaths, can China’s alternative regulatory path still be trusted?
文献与产业新闻精选评分7373 Tavneos trial flagged for 'serious breaches' of protocol as EU regulators dissect market withdrawal decision
文献与产业新闻评分5151 Capricor soars on plan to amend DMD filing after adcomm setback
文献与产业新闻精选评分8282 BMS bags first FDA approval for CELMoD franchise with Zenbexus multiple myeloma nod
文献与产业新闻评分4646 Two years after rules overhaul, have methadone clinics really changed?
文献与产业新闻评分5454 How will legal challenges fare against CMS rule on gender-affirming care?
中文产业新闻精选Chinese source评分7777 FDA 批准 BMS Iberdomide 联合方案上市，治疗复发难治多发性骨髓瘤
中文产业新闻Chinese source评分6161 国家医保局印发《检验类医疗服务价格项目立项指南（试行）》
中文产业新闻精选Chinese source评分8282 康方生物依沃西联合化疗一线治疗鳞状非小细胞肺癌获NMPA批准
中文产业新闻精选Chinese source评分7676 FDA 加速批准 BMS Zenbexus 联合方案治疗复发多发性骨髓瘤
文献与产业新闻评分4040 Global drugs that made the grade in China in 2025
中文产业新闻精选Chinese source评分7171 天境生物与渤健宣布菲泽妥单抗在中国获批上市，为该产品全球首次获批
中文产业新闻精选Chinese source评分7070 国家药监局批准注射用菲泽妥单抗上市，联合来那度胺和地塞米松用于多发性骨髓瘤二线及以上治疗
中文产业新闻精选Chinese source评分7272 礼来口服GLP-1药物Orforglipron（Foundayo）英国获批双适应症上市
文献与产业新闻评分3030 STAT+: Kennedy heads west, slams Becerra
文献与产业新闻评分2727 You've got the grades, but don't pass on your health
文献与产业新闻评分3939 STAT+: Newsom promotes affordable insulin, but California’s generic label is off to a slow start
文献与产业新闻评分3737 STAT+: What Medicare incentives for AI-based devices mean for tech companies — and hospitals
文献与产业新闻评分5353 STAT+: Providers notch No Surprises Act legal win that could boost their pay
中文产业新闻精选Chinese source评分7676 康方生物依沃西联合化疗一线治疗鳞状非小细胞肺癌获NMPA批准
中文产业新闻精选Chinese source评分7171 多款创新医疗器械获NMPA批准上市，含国内首创产品
中文产业新闻Chinese source评分6666 济川药业小儿通便颗粒获NMPA批准上市，系中药注册新规后首个证候主治中药创新药
中文产业新闻Chinese source评分6565 中因科技ZVS101e注射液拟纳入CDE优先审评
中文产业新闻精选Chinese source评分7171 首个口服PCSK9抑制剂Enlicitide获FDA批准上市
中文产业新闻精选Chinese source评分7878 恒瑞HER2 ADC瑞康曲妥珠单抗获NMPA批准，用于HER2阳性结直肠癌后线治疗
中文产业新闻Chinese source评分6161 九典制药中药1.1类骨科创新药椒七止痛凝胶贴膏获批上市
中文产业新闻精选Chinese source评分6969 药捷安康 1 类创新药替恩戈替尼获批上市，用于 FGFR2 融合胆管癌
中文产业新闻Chinese source评分6060 正大天晴安罗替尼第12个适应症获批，联合贝莫苏拜单抗一线治疗晚期肺鳞癌
中文产业新闻精选Chinese source评分7373 FDA 批准 Moderna 流感 mRNA 疫苗 mFLUSIVA 上市，为第三类获批 mRNA 疫苗
中文产业新闻Chinese source评分6161 诺和诺德口服司美格鲁肽14mg国内获批心血管新适应症，两项代谢适应症申报FDA
中文产业新闻精选Chinese source评分7171 药捷安康FGFR抑制剂替恩戈替尼片获NMPA批准上市
中文产业新闻精选Chinese source评分8080 武田OX2R激动剂Oveporexton获FDA批准用于成人1型发作性睡病
中文产业新闻Chinese source评分6767 华奥泰国产IL-36R单抗获批用于成人泛发性脓疱型银屑病
中文产业新闻精选Chinese source评分6868 药捷安康多靶点激酶抑制剂替恩戈替尼片获NMPA批准上市
中文产业新闻精选Chinese source评分7373 恒瑞 HER2 ADC 瑞康曲妥珠单抗获 NMPA 批准用于 HER2 阳性结直肠癌后线治疗
中文产业新闻精选Chinese source评分8383 武田奥普雷顿获FDA批准，用于成人1型发作性睡病NT1